REUTERS: UnitedHealth Group Inc will stick with its decision to pass on drug maker discounts to patients to help them beat rising medicine prices despite the U.S. government having withdrawn a similar proposed policy in its health programs, its top executive said on Thursday.
"We think UnitedHealth is underperforming the peers today likely because on the call, they guided 2019 revenues to now be 'at or slightly below' the prior revenue guidance range of US$243-245 billion," Scott Fidel an analyst at Stephens said. Wichmann said the government's decision showed that the Trump administration values pharmacy benefit managers as a"counterbalance" to drug prices.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: